High-Flow Nasal Cannula Therapy for Exertional Dyspnea in Patients with Cancer: A Pilot Randomized Clinical Trial
Authors:
Open Access
- 2 December 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 26 (8) , e1470-e1479
Abstract
Background: Exertional dyspnea is common in patients with cancer and limits their function. The impact of high-flow nasal cannula on exertional dyspnea in nonhypoxemic patients is unclear. In this double-blind, parallel-group, randomized trial, we assessed the effect of flow rate (high vs. low) and gas (oxygen vs. air) on exertional dyspnea in nonhypoxemic patients with cancer.Patients and Methods: Patients with cancer with oxygen saturation >90% at rest and exertion completed incremental and constant work (80% maximal) cycle ergometry while breathing low-flow air at 2 L/minute. They were then randomized to receive high-flow oxygen, high-flow air, low-flow oxygen, or low-flow air while performing symptom-limited endurance cycle ergometry at 80% maximal. The primary outcome was modified 0–10 Borg dyspnea intensity scale at isotime. Secondary outcomes included dyspnea unpleasantness, exercise time, and adverse events.Results: Seventy-four patients were enrolled, and 44 completed the study (mean age 63; 41% female). Compared with low-flow air at baseline, dyspnea intensity was significantly lower at isotime with high-flow oxygen (mean change, −1.1; 95% confidence interval [CI], −2.1, −0.12) and low-flow oxygen (−1.83; 95% CI, −2.7, −0.9), but not high-flow air (−0.2; 95% CI, −0.97, 0.6) or low-flow air (−0.5; 95% CI, −1.3, 0.4). Compared with low-flow air, high-flow oxygen also resulted in significantly longer exercise time (difference + 2.5 minutes, p = .009), but not low-flow oxygen (+0.39 minutes, p = .65) or high-flow air (+0.63 minutes, p = .48). The interventions were well tolerated without significant adverse effects.Conclusion: Our preliminary findings support that high-flow oxygen improved both exertional dyspnea and exercise duration in nonhypoxemic patients with cancer. (ClinicalTrials.gov ID: NCT02357134).Implications for Practice: In this four-arm, double-blind, randomized clinical trial examining the role of high-flow nasal cannula on exertional dyspnea in patients with cancer without hypoxemia, high-flow oxygen, but not high-flow air, resulted in significantly lower dyspnea scores and longer exercise time. High-flow oxygen delivered by high-flow nasal cannula devices may improve clinically relevant outcomes even in patients without hypoxemia.Keywords
This publication has 49 references indexed in Scilit:
- High-Flow Nasal Cannula Therapy in Do-Not-Intubate Patients With Hypoxemic Respiratory DistressRespiratory Care, 2013
- Attrition rates, reasons, and predictive factors in supportive care and palliative oncology clinical trialsCancer, 2012
- Inhaled Fentanyl Citrate Improves Exercise Endurance During High-Intensity Constant Work Rate Cycle Exercise in Chronic Obstructive Pulmonary DiseaseJournal of Pain and Symptom Management, 2012
- Humidified High-Flow Nasal Oxygen Utilization in Patients with Cancer at Memorial Sloan-Kettering Cancer CenterJournal of Palliative Medicine, 2011
- Effect of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnoea: a double-blind, randomised controlled trialThe Lancet, 2010
- Research in high flow therapy: Mechanisms of actionRespiratory Medicine, 2009
- Dyspnea—A Bad Prognosis Symptom at the End of LifeAmerican Journal of Hospice and Palliative Medicine®, 2009
- Symptom Prevalence, Intensity, and Distress in Patients With Inoperable Lung Cancer in Relation to Time of DeathJournal of Clinical Oncology, 2007
- A Nasal Cannula can be used to Treat Obstructive Sleep ApneaAmerican Journal of Respiratory and Critical Care Medicine, 2007
- The Effects of High-Flow vs Low-Flow Oxygen on Exercise in Advanced Obstructive Airways DiseaseChest, 2004